Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
| Revenue (TTM) | $60.70M |
| Gross Profit (TTM) | $45.72M |
| EBITDA | $8.48M |
| Operating Margin | 14.00% |
| Return on Equity | 12.80% |
| Return on Assets | 4.05% |
| Revenue/Share (TTM) | $1.56 |
| Book Value | $1.97 |
| Price-to-Book | 6.83 |
| Price-to-Sales (TTM) | 7.59 |
| EV/Revenue | 8.2 |
| EV/EBITDA | 41.85 |
| Quarterly Earnings Growth (YoY) | 59.80% |
| Quarterly Revenue Growth (YoY) | 35.40% |
| Shares Outstanding | $40.25M |
| Float | $24.10M |
| % Insiders | 2.59% |
| % Institutions | 29.64% |
Volatility is currently expanding
BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol.
Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity
The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base.
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025
BrainsWay is transitioning from a device manufacturer to a capital-light ecosystem provider for interventional psychiatry, leveraging recurring revenue and minority investments. BWAY reported Q1-2026 revenue up 35% YoY, a steady 75% gross margin, and expects FY-2026 revenue of $66–68M with adjusted EBITDA growth of 86–100%. Multi-year leasing, accelerated protocols, and expanded provider access are reducing TMS adoption barriers, supporting higher utilization and stickier customer relationships.
Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BWAY and any ticker you trade — then tracks every position and per-strategy win rate.
